Silence Therapeutics (SLN) Set to Announce Quarterly Earnings on Wednesday

Silence Therapeutics (NASDAQ:SLN – Get Rating) will be announcing its earnings results before the market opens on Wednesday, March 15th. Analysts expect the company to announce earnings of $0.45 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $10.09 on Wednesday. Silence Therapeutics has a 12 month low of $7.80 and a 12 month high of $21.32. The company has a market capitalization of $301.99 million, a price-to-earnings ratio of -6.64 and a beta of 0.88. The firm’s fifty day moving average price is $13.28 and its 200 day moving average price is $12.66.

Institutional Trading of Silence Therapeutics

Several institutional investors have recently added to or reduced their stakes in SLN. Citadel Advisors LLC acquired a new stake in Silence Therapeutics in the 2nd quarter valued at about $136,000. Millennium Management LLC raised its position in Silence Therapeutics by 19.8% during the fourth quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock valued at $266,000 after acquiring an additional 2,879 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Silence Therapeutics during the fourth quarter valued at approximately $450,000. UBS Group AG raised its position in Silence Therapeutics by 4.8% during the fourth quarter. UBS Group AG now owns 69,006 shares of the company’s stock valued at $1,052,000 after acquiring an additional 3,191 shares in the last quarter. Finally, Morgan Stanley raised its position in shares of Silence Therapeutics by 36.0% in the fourth quarter. Morgan Stanley now owns 210,973 shares of the company’s stock valued at $3,217,000 after purchasing an additional 55,814 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SLN shares. Chardan Capital cut their target price on shares of Silence Therapeutics from $33.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, November 17th. HC Wainwright lowered their target price on shares of Silence Therapeutics from $95.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, December 6th. Morgan Stanley initiated coverage on shares of Silence Therapeutics in a research note on Friday, December 9th. They set an “equal weight” rating and a $18.00 price objective for the company. Finally, Robert W. Baird boosted their price objective on shares of Silence Therapeutics from $50.00 to $53.00 in a research note on Thursday, January 26th.

Silence Therapeutics Company Profile

(Get Rating)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.